Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05640843 · ClinicalTrials.gov registry record · NA

A Study Comparing a Plant-Based Diet With Supplements and Placebo in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)

A NA study of Smoldering Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance, sponsored by Memorial Sloan Kettering Cancer Center.

Recruiting
Registry status
NA
Development phase
150
Enrollment target
8
Study locations

NCT05640843 is a NA study of Smoldering Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance that is actively recruiting participants, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 150 participants, below the 792-participant average among 20 other Smoldering Multiple Myeloma trials with a reported enrollment target (81% lower). The trial reports 8 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05640843, a NA study of Smoldering Multiple Myeloma and Monoclonal Gammopathy of Undetermined Significance, is actively recruiting participants, sponsored by Memorial Sloan Kettering Cancer Center.

RECRUITING
Registry status
NA
Development phase
150 participants
Enrollment target
8
Study locations

Study Summary

The researchers are doing this study to look at how butyrate levels change in participants' stool after they are on a- plant-based diet for at least 12 weeks. All participants will have monoclonal gammopathy of undetermined significance (MGUS) or smoldering multiple myeloma (SMM). We will compare how the plant-based diet, omega-3 fatty acid and curcumin supplements, and placebo (an inactive substance that looks like the study supplements) affect butyrate levels in participants' stool.

Interventions

  • OTHER Whole Foods Plant-based Diet
  • DIETARY_SUPPLEMENT Algae Omega 3 + Curcumin
  • OTHER Placebo supplements

Study Locations (8)

New York

  • Memorial Sloan Kettering Suffolk- Commack (All Protocol Activities) - Commack
  • Memorial Sloan Kettering Westchester (All Protocol Activities) - Harrison
  • Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
  • Memorial Sloan Kettering Nassau (All Protocol Activities) - Uniondale

New Jersey

  • Memorial Sloan Kettering Basking Ridge (All Protocol Activities) - Basking Ridge
  • Memorial Sloan Kettering Monmouth (All Protocol Activities) - Middletown
  • Memorial Sloan Kettering Bergen (All Protocol Activities) - Montvale

Georgia

  • Emory University (Data Collection Only) - Atlanta

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2022-11-29
Est. Completion 2026-11
Phase NA

Sponsor

Memorial Sloan Kettering Cancer Center

1,884 total trials

What the Registry Record Tells You About NCT05640843

The ClinicalTrials.gov registry entry for NCT05640843 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 792-participant average among 20 other Smoldering Multiple Myeloma trials with a reported enrollment target (81% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Smoldering Multiple Myeloma appearing as the primary indexed condition, and to 3 interventions - of which Whole Foods Plant-based Diet is the first listed.

NCT05640843 reports 8 study locations spanning 3 distinct geographic areas - top geographies include New York, New Jersey, Georgia.

Frequently Asked Questions

What is clinical trial NCT05640843 about?

NCT05640843 is a clinical study titled "A Study Comparing a Plant-Based Diet With Supplements and Placebo in People With Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)". The researchers are doing this study to look at how butyrate levels change in participants' stool after they are on a- plant-based diet for at least 12 weeks. All participants will have monoclonal gammopathy of undetermined significance (MGUS) or smoldering multiple myeloma (SMM). We will compare ho...

What is the current status of trial NCT05640843?

This trial is currently recruiting. It is a NA study. The enrollment target is 150 participants. The study started on 2022-11-29. Estimated completion is 2026-11.

What conditions does trial NCT05640843 study?

This clinical trial studies the following conditions: Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance.

What interventions are being tested in trial NCT05640843?

The interventions under investigation include: Whole Foods Plant-based Diet (OTHER), Algae Omega 3 + Curcumin (DIETARY_SUPPLEMENT), Placebo supplements (OTHER).

Who is sponsoring clinical trial NCT05640843?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05640843 being conducted?

This trial has 8 study locations across Georgia, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Smoldering Multiple Myeloma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.